Table 2.

Serum level of YKL-40 is an independent prognostic variable of overall survival in cancer patients

DiagnosisHazards ratio (95% confidence intervals)PReference
Primary breast cancer (n = 271)1.8 (1.0-3.1)0.04Johansen et al. (91)
Metastatic breast cancer (n = 100)2.6 (1.6-4.1)0.0002Jensen et al. (90)
Colorectal cancer (n = 603)1.4 (1.1-1.8)0.007Cintin et al. (84)
Ovarian cancer stage III (n = 47)4.0 (1.5-10.3)0.005H√łgdall et al. (89)
Recurrent ovarian cancer (n = 73)2.3 (1.3-4.1)0.006Dehn et al. (87)
Small cell lung cancer (n = 131)1.9 (1.1-3.4)0.02Johansen et al. (92)
Metastatic prostate cancer (n = 129)1.3 (1.0-1.7)0.02Brasso et al. (86)
Metastatic renal cell cancer (n = 58)4.1 (1.9-8.8)0.001Geertsen et al. (88)
Metastatic melanoma (n = 110)1.9 (1.2-2.8)0.004Schmidt et al. (93)
  • NOTE: These results are from multivariate Cox regression analyses applying routinely used prognostic variables. These cancer patients were scored as having elevated serum YKL-40 if it was higher than the upper 95th percentile confidence limit of serum YKL-40 in healthy subjects adjusted for age (se also footnotes to Table 1).